• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.199-199
• /
• 1994

Thioglycerol과 glycerol로부터 rac-1-S-octa-decyl-2-O-palmitoyl-1-S-thioglycerol-3-phosphate (DL -PTBA-P)와 rac-1-O-octadecyl-2-O-palmitoyl-g1ycerol-3-phosphate (DL-PBA-P)등을 합성하였고, 이들에 ara-C 유도체인 ara-CMP morpholidate를 반응시켜 최종 산물인 ara-CDP-DL-PCA, ara-CDP-DL-PBA, ara-CDP-DL-PTCA 및 ara-CDP-DL-PTBA등을 합성하였다. 이들 최종산믈의 항암효과는 L1210 lymphoid leukemia, colon 26 carcioma, M5076 sarcoma, C-1300 neuroblastoma, 3-Lewis lung carcinoma, WEHI-3B leukemia, human colon cancer, hum an pancreatic cancer 등의 암세포주를 사용하여 실험하였다. L1210를 DB/2J의 뇌막 또는 복강, DBA/1J의 복강내에 이식하여 ara-C, Ehss thioether lipid의 ara-C 유도체 (ara-CDP-L-DP, ara-CDP-DL-PCA, ara-CDP-DL-PBA, ara -CDP-DL-PTCA, ara-CDP-D-PTBA, ara-CDP-L-PTBA, ara-CDP-DL-PTBA)를 단일 투여 또는 중복 투여하였고, 3-Lewis는 C57BL/6 의 발바닥 피하, colon26은 BALB/C의 견갑상부 히아조직, M5076은 C57BL/6의 피하, WEHI-3B는 BALB/C의 복강, C-1300는 A/strong Ros에 각각 이식한 후 ara-C 또는 ara-CDP-DL-PTBA를 단일 또는 중복 투여하였다.

• 대한한의학방제학회지
• /
• 제24권2호
• /
• pp.71-79
• /
• 2016

Objectives : To verify the equivalence between Atractylodis Rhizoma Alba herbal prescription(HP-ARA) and Atractylodis Rhizoma Alba herbal sub stance(HS-ARA). Methods : Safety tests by microbial regulation and heavy metal analysis (total heavy metal, Pb, As) and a stability test by long term shelf test for HP-ARA according to notification of the Ministry of Food and Drug Safety were carried out. Then, multi component profile of HP-ARA and HS -ARA were analyzed by HPLC. Results : The safety and stability of HP-ARA confirmed by several tests. Correlation coefficient of equivalence of HP-ARA and ARA-HS showed 0.992. Conclusion : Based on this result of equivalence between HP-ARA and HS-ARA, HP-ARA can substitute HS-ARA used to make herbal medicines (herbal decoction, pills and powder).

• 한국동물학회지
• /
• 제23권4호
• /
• pp.203-218
• /
• 1980

DNA회복합성과 염색체이상, 자매염색분체 교환 및 복제억제 현상과의 연관성을 추구하기 위해서 $HF_1$, CHO 및 $HeLa S_3$ 세포를 재료로 자외선 또는 MMS를 처리하기전 또는 후에 ara-C를 처리하여 그 효과를 비교 검토하였다. (1) Ara-C는 자외선 및 MMS에 의한 DNA회복합성을 억제하였으며 이 억제효과는 ara-C를 후 처리한 경우 더욱 현저하였다. (2) Ara-C는 자외선이나 MMS에 의한 염색체 이상율을 증가시켰다. 특히 MMS 처리후 ara-C를 처리한 실험군에서는 염색체이상율이 상승효과를 보였는데 이는 염색분체 절단이 증가된 때문이었다. (3) Ara-C는 염색체이상에서와는 달리 자외선이나 MMS에 의한 자매염색분체 교환율을 증가시키지 않았다. 이는 특히 MMS군에서 전처리한 경우에 뚜렷하였다. (4) Ara-C를 처리하면 DNA합성율이 즉시 감소했다가 회복되었다. 그러나 ara-C와 자외선 EH는 MMS를 복합처리하면 DNA 합성양상이 처음에는 ara-C의 영향처럼 보이다가 뒤에는 자외선 또는 MMS에 의한 반응과 같이 나타났다. 이같은 결과들은 ara-C가 DNA 상해요인이 아님에도 염색체이상 또는 염색체분체교환 유발요인으로 작용함을 나타내며, DNA 회복기작이 염색체이상, 자매염색분체교환 및 복제억제 현상과 직접적인 상관성이 없음을 시사하는 것이다.

• 약학회지
• /
• 제32권5호
• /
• pp.334-339
• /
• 1988

AraC-5'-methylthioacetate (araC-MTA, 1) and araC-5'-butylthioacetate (araC-BTA, 2) were prepared and their physical and chemical properties and in vivo antitumor activities were examined. Both compounds were found to have higher partiton coefficients (n-hexanol/water) than their parent araC and to be hydrolyzed to araC within an hour in mouse plasma and ascitic fluid solutions. In in vivo antitumor activity test they showed similar potency to araC, which were assumed due to too quick hydrolyses of them to parent in the body fluid.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1995년도 춘계학술대회
• /
• pp.85-85
• /
• 1995

전년도에 ara-C 유도체 중에서 ara-CDP-DL-PTBA가 각종 암세포주에 대한 뛰어난 항암작용이 보고된바 있으며, 이후 시료의 대량확보, Bulk Formulation 및 전임상등의 세가지 분야에 관해 연구를 수행하였다. Ara-CDP-DL-PTBA를 수용액에 현탁, 초음파분쇄후 NICOMP Analysis에 의하여 micellar solution의 입자도를 알아 본 결과 fresh prepared micelles은 11,1mm size가 88.63%이며 50,5mm가 11.37%로 나타나 평균 19,0mm가 되고, Reconstructed micells은 10.9mm size가 99.87%이며 356.1mm가 0.13%로 나타나 평균 11.0mm가 된다. Ara-C와 Ara-CDP-DL-PTBA의 대사작용을 알아본 결과, ara-C는 투여 1시간째 2,850 $\pm$ 450 pmol, 4시간째 450$\pm$190 pmol, 24시간째 30 pmol 이하로 ara-CTP의 혈중 농도가 급격히 감소하는 반면에 ara-CDP-DL-PTBA는 1시간째 650$\pm$120 pmol, 2시간째 1,800$\pm$500 pmol, 24시간째 300$\pm$90 pmol으로 ara-CTP의 혈중 농도가 서서히 감소하였다.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.167-167
• /
• 1994

Thioglycerol과 Glycerol을 출발물질로 1번 탄소(C) 위치의 산소(O),또는 황(S)에 octadecyl기로 alkylation한 후, 2번 탄소(C)위치 산소(O)를 palmitoyl기로acetylation시켜 만든 thioether lipid 및 ether lipid유도체를 인산화시킨 rac-1-S-octa-decyl-2-O-palmitoyl-1-S-thioglycerol-3-phosphate (DL-PTBA-P)와 rac-1-O-octadecyl-2-O-palmitoylglycerol-3-phosphate (DL-PBA-P)등을 합성하였다. 이들 thioether lipid 및 ether lipid유도체는 그 자체로도 in vitro와 in vivo에서anti-neoplastic property를 가지고 있는데, 이들 중간체를 핵산 화합물로써 역시 강한 항암 작용에도 불구하고 독성등 부작용이 문제가 되고있는 Ara-C (일명 Cytarabine)의 인산화물인 ara-CMP morpholidate와 conjugation시켜 최종물질로서 ara-CDP-DL-PCA, ara-CDP-DL-PBA, ara-CDP-DL-PTCA 및 ara-CDP-DL-PTBA등을 합성하였다. 이들 중 ara-CDP-DL-PTBA가 본 과제와 관련하여 항암제로서 최종 개발하고자하는 주요 물질인 Cytoros이다.

• Archives of Pharmacal Research
• /
• 제12권2호
• /
• pp.88-93
• /
• 1989

In order to obtain some informations about the effect of molecular weight on the release rate of drug from drug carrier, two types of poly-L-glutamic acid (PLGA)-cytarabine (ara-C) conjugates, PLGA-ara-C:I and PLGA-ara-C:II, were synthesized using two types of PLGA having different average molecular weight, 43,000 and 77,800, respectively. The PLGA-ara-C conjugates were synthesized by mixed anhydride method and found to be covalently linked. Both types of conjugates charged negatively at biological pH. The pH-dependent release rate of ara-C was observed in both cases, and the release rate was accelerated in basic, acidic conditions (the k values were 0.015 $day^{-1}$ at pH 7.0, 0.024 $day^{-1}$ at pH 5.0, and 0.059 $day^{-1}$ at pH 9.0 in the case of PLGA-ara-C:I) and in the presence of pretense. The time required for the release of 16.5% of ara-C from PLGA-ara-C:I were 8 hr and 144 hr in the presence and absence of protease, respectively. Although both types of conjugates showed similar drug substitution ratio, they showed different release rates. Between the two types of conjugates, PLGA-ara-C:II showed the faster release rate (0.030 vs 0.042 $day^{-1}$ in pH 7.4 phosphate buffer solution at $37^{\circ}C$) and the smaller activation energy for the release of drug (12.5 vs 7.7 Kcal/mol) than PLGA-ara-C:I. The characteristic effect of molecular weight on the release rates of PLGA-ara-C conjugates suggests that the drug release rate might be effectively controlled over a prolonged period of time by the combined use of the different types of PLGA-ara-C conjugates having different molecular weights.

• 한국동물생명공학회지
• /
• 제37권4호
• /
• pp.239-245
• /
• 2022

Protein and peptide candidates are screened to apply therapeutic application as a drug. Ensuring that these candidates are delivered and maximized effectiveness is still challenging and a variety of studies are ongoing. As drug delivery system vehicles, cell-penetrating peptide (CPP) can deliver various kinds of cargo into the cell cytosol. In a previous study, we developed Ara27 CPP, which are a zinc knuckle family protein of Arabidopsis, and confirmed internalization in human dermal fibroblasts and human dental pulp stem cells at low concentration with short time treatment condition without any toxicity. Ara27, an amphipathic CPP, could be modified and utilized in the biomedical field excluding the risk of toxicity. Therefore, we would like to confirm the non-toxic induced penetrating ability of Ara27 in various cell lines. The purpose of this study was to screen the cell internalization ability of Ara27 in various cell lines and to confirm Ara27 as a promising core CPP structure. First, Ara27 was screened to confirm non-toxicity concentration. Then, fluorescence-labeled Ara27 was treated on human normal cell lines, cancer cell lines and animal cell lines to identify the cellular internalization of Ara27. Ara27 was well intracellular localized in all cell lines and the intensity of fluorescence was remarkably increased in time pass manner. These results indicate that Ara27 has the potential as a core structure for applications in various drug delivery systems.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.200-200
• /
• 1994

Thioglycerol과 g1ycerol로부터 rac-1-S-octa-decyl-2-O-palmitoyl-1-S-thioglycerol-3-phosphate (DL -PTBA-P)와 rac -1-O-octadecyl -2-O-palmitoyl-g1ycerol-3-phosphate (DL-PBA-P)등을 합성하였고, 이들에 ara-C유도체인 ara-CMP morpholidate를 반응시켜 최종 산물인 ara-CDP-DL-PCA, ara-CDP-DL-PBA, ara-CDP-DL-PTCA 및 ara-CDP-DL-PTBA등을 합성하였다. 이들 최종 산물의 항암효과는 L1210 lymphoid leukemia, P388 leukemia등의 암세포주를 사용하여 실험하였다. 암세포인 L1210, P388 leukemia 세포의 성장에 대한ara-CDP-DL-PTBA의 시험관 내 세포성장 억제정도를 알아보기 위하여 비색법인 MTT방법을 시행하였으며, 검체의 세포성장 억제능을 비교하기 위하여 대조군으로 5-Fluorouracil (5-FU)을 사용하였다.

• Journal of Pharmaceutical Investigation
• /
• 제36권4호
• /
• pp.283-286
• /
• 2006

The present study aimed to investigate the interaction of nucleoside analogs with human organic anion transporter 1 and 3(hOAT1 and hOAT3) that play a primary role in the tubular uptake of endogenous and exogenous organic anions in the kidney. The interactions of ddC, ara-C, ara-A and ara-U with hOAT1 and hOAT3 were examined using MDCK cells stably overexpressing hOAT1 or hOAT3. Among the tested drugs, ddC showed the highest affinity to hOAT1 with $IC_{50}$ values of 5.2 mM, while ara-A, ara-C and ara-U weakly inhibited the cellular uptake of $[^3H]-PAH$ in MDCK-hOAT1 cells at 1 mM. In contrast, all the tested drugs did not have any inhibition effect on the cellular uptake of $[^3H]-estrone$ sulfate in MDCK-hOAT3 cells over the drug concentration of 0.01-2 mM, implying that they might not interact with hOAT3. Taken all together, the present study suggests that hOAT1 could weakly interact with nucleoside analogues such as ddC, ara-C, ara-A and ara-U but the interaction with hOAT3 during the urinary excretion of these nucleoside analogues may be negligible in the kidney.